VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, is the first to demonstrate the isolation and analysis of >99% pure circulating tumor-derived DNA (ctDNA).
An innovative platform developed by PKU researchers called "cf-EpiTracing" has proved capable of detecting and tracing ...
IgA nephropathy, an immune assault on the kidneys, is often missed. New treatments mean that spotting it sooner might save lives ...
RIKEN researchers have demonstrated a method that can detect tiny amounts of biomarkers in liquid samples and can distinguish between highly similar biomarkers. This promises to boost the versatility ...
Targets $36 Billion TAM in Early Cancer Detection and MRD. Company in active discussions with global diagnostic leaders to accelerate commercialization. HENDERSON, Nev., March 18, ...
Scientists have developed a highly accurate blood test that can detect brain tumours, including aggressive glioblastomas, ...
Shields Gazette on MSN
Man told shoulder pain was acid reflux diagnosed with terminal blood cancer
A man who was told his shoulder pain was due to acid reflux discovered he had incurable blood cancer - after pushing for a second opinion.
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company and its research ...
VolitionRx (VNRX) stock jumped 70% in pre-market after achieving 99% pure tumor DNA isolation and detecting 49/49 cancers in a blind study.
Rectal bleeding and renal dysfunction in an older patient led to a biopsy that reveals systemic amyloidosis, highlighting a rare gastrointestinal presentation.
The bump had been present for about 3 months. The patient’s mother said there had been no bleeding, tenderness, color change, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results